Enanta downgraded to Underweight from Neutral at JPMorgan JPMorgan analyst Eric Joseph downgraded Enanta Pharmaceuticals to Underweight from Neutral and lowered his price target for the shares to $57 from $86. Read more at: https://thefly.com/landingPageNews.php?id=2968060